| dc.creator |
Kaplan, Mehmet Ali |
|
| dc.creator |
Benekli, Mustafa |
|
| dc.creator |
Coskun, Ugur |
|
| dc.creator |
Buyukberber, Suleyman |
|
| dc.creator |
Cetin, Bulent |
|
| dc.creator |
Isikdogan, Abdurahman |
|
| dc.creator |
Ozkan, Metin |
|
| dc.creator |
Tufan, Gulnihal |
|
| dc.creator |
Afsar, Barış |
|
| dc.creator |
Berk, Veli |
|
| dc.date |
2013-06-01T00:00:00Z |
|
| dc.date.accessioned |
2021-12-03T11:19:19Z |
|
| dc.date.available |
2021-12-03T11:19:19Z |
|
| dc.identifier |
297d1109-14c7-49ee-9a91-878b16213e20 |
|
| dc.identifier |
10.1016/j.clgc.2012.09.001 |
|
| dc.identifier |
https://avesis.sdu.edu.tr/publication/details/297d1109-14c7-49ee-9a91-878b16213e20/oai |
|
| dc.identifier.uri |
http://acikerisim.sdu.edu.tr/xmlui/handle/123456789/90564 |
|
| dc.description |
In this study, we have undertaken a retrospective review of 100 patient charts to investigate whether neutrophil to lymphocyte ratio (NLR) is associated with progression-free survival (PFS) in metastatic renal cell carcinoma (mRCC) patients treated with second-line vascular endothelial growth factor (VEGF) targeted tyrosine kinase inhibitors (TKIs) after failure of interferon-alpha. We have shown that NLR at diagnosis is an independent predictor of survival in mRCC patients. Investigation of therapies which harness the immune response are warranted in this disease. |
|
| dc.language |
eng |
|
| dc.rights |
info:eu-repo/semantics/closedAccess |
|
| dc.title |
Is the Pretreatment Neutrophil to Lymphocyte Ratio an Important Prognostic Parameter in Patients with Metastatic Renal Cell Carcinoma? |
|
| dc.type |
info:eu-repo/semantics/article |
|